journal article·2015-07-28

Gd–Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1

Yuanming Pan, Liming Wang, Seung-gu Kang, Youyong Lu, Zaixing Yang, Tien Huynh, Chunying Chen, Ruhong Zhou, Mingzhou Guo, Yuliang Zhao

ACS Nano· Volume 9· Issue 7
Publisher page

Abstract

The treatment of pancreatic cancer frequently fails due to local recurrence and hepatic metastasis. Our previous study found that Gd@C82(OH)22 can suppress pancreatic cancer by inhibiting MMP-2/9 expression. In this study, we further explored the epigenetic mechanism of Gd@C82(OH)22 in human pancreatic cancer metastasis. Gd@C82(OH)22 suppressed tumor metastasis through down-regulation of metastasis-associated protein 1 (MTA1), HDAC1, HIF-1α, and MMP-2/9 and up-regulation of reversion-cysteine protein with the Kazal motif (RECK). The level of acetylation was increased in the promoter region of the RECK gene after Gd@C82(OH)22 treatment. The interaction of MTA1, HDAC1, and HIF-1α was inhibited by Gd@C82(OH)22. Furthermore, large-scale molecular dynamics simulations revealed Gd@C82(OH)22 could serve as an effective HDAC inhibitor to the protein-protein association between HDAC1 and MTA1, especially through MTA1's SANT and ELM2 dimerization domains. Our findings implicate Gd@C82(OH)22 as a novel HDAC inhibitor acting to increase RECK expression by suppressing the MTA1/HDAC1 co-repressor complex. Gd@C82(OH)22 may serve as a potential HDAC1 inhibitor to suppress pancreatic cancer cell invasion and metastasis both in vitro and in vivo. According to computer analysis and experimental validation, Gd@C82(OH)22 activates RECK expression by inhibiting the interaction of HDAC1 and MTA1.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Histone Deacetylase Inhibitors Research · Peptidase Inhibition and Analysis · Signaling Pathways in Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology and Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100190, China

Computational Biology Center, IBM Thomas J. Watson Research Center,1101 Kitchawan Road, Yorktown Heights, New York 10598, United States

Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

Institute of Quantitative Biology and Medicine, SRMP and RAD-X, Soochow University, Suzhou 215123, China

Funding

National Key Scientific Instrument Special Program · National Natural Science Foundation of China · Ministry of Science and Technology of the People's Republic of China

References (67)

Show source-provided references
1. Siegel R. · CA-Cancer J. Clin. · 2014 · 64 · 910.3322/caac.21208 ↗
2. Yadav D. · Gastroenterology · 2013 · 144 · 125210.1053/j.gastro.2013.01.068 ↗
3. Bosetti C. · Mol. Carcinog. · 2012 · 51 · 310.1002/mc.20785 ↗
4. Neoptolemos J. P. · N. Engl. J. Med. · 2004 · 350 · 120010.1056/NEJMoa032295 ↗
5. Yoo Y. G. · Oncogene · 2008 · 27 · 340510.1038/sj.onc.1211000 ↗
6. Toh Y. · J. Exp Clin. Cancer Res. · 2000 · 19 · 105
7. Jeon H. W. · Mol. Cancer Ther. · 2010 · 9 · 136110.1158/1535-7163.MCT-09-0717 ↗
8. Oh J. · Cell · 2001 · 107 · 78910.1016/S0092-8674(01)00597-9 ↗
9. Masui T. · Clin. Cancer Res. · 2003 · 9 · 1779
10. Noda M. · Cancer Metastasis Rev. · 2003 · 22 · 16710.1023/A:1023043315031 ↗
11. Takagi S. · Cancer Res. · 2009 · 69 · 150210.1158/0008-5472.CAN-08-2635 ↗
12. Silveira Correa T. C. · J. Cell. Biochem. · 2010 · 110 · 5210.1002/jcb.22472 ↗
13. Liu L. T. · Cancer Res. · 2003 · 63 · 3069
14. Chang H. C. · Cell Signal · 2004 · 16 · 67510.1016/j.cellsig.2003.11.001 ↗
15. Vadlapatla R. K. · Curr. Drug Targets · 2013 · 14 · 91910.2174/13894501113149990015 ↗
16. Yang M. H. · Cell Cycle · 2008 · 7 · 209010.4161/cc.7.14.6324 ↗
17. Miyake S. · Int. J. Oncol. · 2013 · 43 · 143110.3892/ijo.2013.2068 ↗
18. Akakura N. · Cancer Res. · 2001 · 61 · 6548
19. Hu H. T. · Acta Pharmacol. Sin. · 2010 · 31 · 10210.1038/aps.2009.181 ↗
20. Balasenthil S. · Cancer Res. · 2007 · 67 · 713210.1158/0008-5472.CAN-07-0750 ↗
21. Nagaraj S. R. · Mol. Carcinog. · 2015 · 54 · 33310.1002/mc.22104 ↗
22. Li Y. · J. Exp. Clin. Cancer Res. · 2013 · 32 · 3310.1186/1756-9966-32-33 ↗
23. Pakala S. B. · Cancer Res. · 2013 · 73 · 376110.1158/0008-5472.CAN-12-3998 ↗
24. Sankaran D. · J. Biol. Chem. · 2012 · 287 · 548310.1074/jbc.M111.324632 ↗
25. Gururaj A. E. · Proc. Natl. Acad. Sci. U.S.A. · 2006 · 103 · 667010.1073/pnas.0601989103 ↗
26. Iguchi H. · Int. J. Oncol. · 2000 · 16 · 1211
27. Mariadason J. M. · Epigenetics · 2008 · 3 · 2810.4161/epi.3.1.5736 ↗
28. Kim Y. J. · Oncogene · 2013 · 32 · 282810.1038/onc.2013.32 ↗
29. Khan O. · Immunol. Cell Biol. · 2012 · 90 · 8510.1038/icb.2011.100 ↗
30. Huang X. · Cancer Res. · 2009 · 69 · 840310.1158/0008-5472.CAN-09-2146 ↗
31. Damaskos C. · Anticancer Res. · 2015 · 35 · 3129
32. Schneider G. · Gut · 2012 · 61 · 32910.1136/gutjnl-2011-301576 ↗
33. Mehdi O. · Pancreatology · 2012 · 12 · 14610.1016/j.pan.2012.02.013 ↗
34. Lehmann A. · BMC Cancer · 2009 · 9 · 39510.1186/1471-2407-9-395 ↗
35. De Souza C. · Recent Pat. Anti-Cancer Drug Discovery · 2015 · 10 · 14510.2174/1574892810666150317144511 ↗
36. Lin K. T. · Clin. Cancer Res. · 2012 · 18 · 469110.1158/1078-0432.CCR-12-0633 ↗
37. Wagner J. M. · Clin. Epigenet. · 2010 · 1 · 11710.1007/s13148-010-0012-4 ↗
38. Chen S. · J. Biomed. Biotechnol. · 2011 · 2011 · 197946
39. Liu T. · Cancer Treat. Rev. · 2006 · 32 · 15710.1016/j.ctrv.2005.12.006 ↗
40. Yin J. J. · Biomaterials · 2009 · 30 · 61110.1016/j.biomaterials.2008.09.061 ↗
41. Wang J. · Biochem. Pharmacol. · 2006 · 71 · 87210.1016/j.bcp.2005.12.001 ↗
42. Kang S. G. · Proc. Natl. Acad. Sci. U.S.A. · 2012 · 109 · 1543110.1073/pnas.1204600109 ↗
43. Meng J. · Integr. Biol. · 2013 · 5 · 4310.1039/c2ib20145c ↗
44. Ushio-Fukai M. · Mol. Cell. Biochem. · 2004 · 264 · 8510.1023/B:MCBI.0000044378.09409.b5 ↗
45. Xia C. · Cancer Res. · 2007 · 67 · 1082310.1158/0008-5472.CAN-07-0783 ↗
46. Akakura N. · Hokkaido Igaku Zasshi · 2001 · 76 · 375
47. Blum R. · Cell Death Dis. · 2014 · 5 · e106510.1038/cddis.2014.38 ↗
48. Afanas’ev I. · Aging Dis. · 2011 · 2 · 219
49. Liu Y. · Nat. Commun. · 2015 · 6 · 598810.1038/ncomms6988 ↗
50. Yin J. J. · Mol. Pharmacol. · 2008 · 74 · 113210.1124/mol.108.048348 ↗
51. Chen C. · Nano Lett. · 2005 · 5 · 205010.1021/nl051624b ↗
52. 10.1111/jcmm.1258310.1111/jcmm.12583 ↗
53. Joseph J. · Oncogene · 2004 · 23 · 630410.1038/sj.onc.1207852 ↗
54. Zgouras D. · Biochem. Biophys. Res. Commun. · 2003 · 300 · 83210.1016/S0006-291X(02)02916-9 ↗
55. Lee Y. M. · Biochem. Biophys. Res. Commun. · 2003 · 300 · 24110.1016/S0006-291X(02)02787-0 ↗
56. Kim M. S. · Nat. Med. · 2001 · 7 · 43710.1038/86507 ↗
57. Jeong S. G. · Cell Biochem. Funct. · 2015 · 33 · 3710.1002/cbf.3084 ↗
58. Du J. · J. Cell. Physiol. · 2015 · 230 · 132110.1002/jcp.24871 ↗
59. Zuo G. · ACS Nano · 2010 · 4 · 750810.1021/nn101762b ↗
60. Zuo G. · J. Phys. Chem. C · 2011 · 115 · 2332310.1021/jp208967t ↗
61. Tsai H.-C. · Cell Res. · 2011 · 21 · 50210.1038/cr.2011.24 ↗
62. Lee K. J. · Biochim. Biophys. Acta · 2010 · 1803 · 60810.1016/j.bbamcr.2010.01.004 ↗
63. Millard C. J. · Mol. Cell · 2013 · 51 · 5710.1016/j.molcel.2013.05.020 ↗
64. Zhou G. · J. Nanosci. Nanotechnol. · 2010 · 10 · 859710.1166/jnn.2010.2486 ↗
65. Zhang M. · J. Nanosci. Nanotechnol. · 2010 · 10 · 855610.1166/jnn.2010.2490 ↗
66. Hait N. C. · Science · 2009 · 325 · 125410.1126/science.1176709 ↗
67. Zheng L. N. · Anal. Bioanal. Chem. · 2015 · 407 · 238310.1007/s00216-014-8422-3 ↗